Core Viewpoint - Workhorse Group Inc. has launched a new W56 Step Van model with a 140 kWh battery, designed specifically for in-city, last-mile package delivery, offering a more affordable option for fleet operators amid rising fuel prices [1][4]. Product Details - The W56 Step Van with a 140 kWh configuration provides an estimated range of 100 miles per charge at full payload, with pricing starting at $169,000, which includes a fully-integrated composite body [2][16]. - The Standard 178" Wheelbase version offers 1,000 cubic feet of cargo space and a payload capacity of 11,000 lbs, while the Expanded 208" Wheelbase version also offers 1,000 cubic feet but with a payload capacity of 10,000 lbs, enhancing stability for larger loads [3]. Market Context - The announcement comes at a time when oil prices have surged, exceeding $100, prompting concerns from analysts about sustained high fuel costs, which are a significant operating expense for fleet operators [5]. - The new model is positioned as a cost-control solution for fleet operators, who face similar fuel price volatility as airlines, allowing them to manage expenses while maintaining operational efficiency [6]. Strategic Implications - The introduction of the 140 kWh model is a result of synergies from Workhorse's merger with Motiv Electric Trucks, aimed at reducing production costs and enhancing operational efficiencies [6]. - Fleet operators can now utilize a mix of 140 kWh and 210 kWh configurations to optimize performance across various delivery routes [6]. Production Capacity - The W56 is currently being produced at Workhorse's facility in Union City, Indiana, which has the capacity to manufacture over 5,000 vehicles annually on a single shift [7].

Core Insights - Rigetti Computing plans to invest up to $100 million in the UK to develop a quantum computing system with over 1,000 qubits within the next 3 to 4 years, marking its first major investment outside the US [1] - The UK government has announced a £2 billion investment program aimed at establishing the UK as a global leader in quantum computing [1][4] Investment and Development - The investment will accelerate quantum computing development in the UK, aligning with the UK's national quantum computing strategy [3] - Rigetti aims to achieve a quantum system capable of one trillion quantum operations (TeraQuOp) by 2035, establishing critical milestones for innovation [3] Collaboration and Ecosystem - Rigetti's presence in the UK has been characterized by successful collaborations across industry, government, and academia, highlighting the UK's commitment to advancing quantum technology [2] - The UK government's focus on end-user engagement and on-premises capabilities is seen as a significant factor in driving the quantum computing sector forward [2][5] Existing Infrastructure - Rigetti has a history of involvement in the UK, including the deployment of a 36-qubit quantum system at the National Quantum Computing Centre, which is part of a consortium focused on quantum error correction [5] - The company operates quantum computers through its Rigetti Quantum Cloud Services (QCS) platform, providing high-performance integration for various clients [8] Technological Advancements - Rigetti's quantum computers utilize superconducting qubits, which are recognized for their maturity and scalability, achieving gate speeds of 50-70 nanoseconds, significantly faster than other modalities [6] - The company has developed the industry's first multi-chip quantum processor and deployed the largest multi-chip quantum computer in 2025 [9]

Core Insights - Artelo Biosciences, Inc. is advancing ART27.13 as a potential treatment for muscle preservation in patients undergoing GLP-1 receptor agonist therapy, addressing a significant unmet need in the biopharma sector [1][4][6] Group 1: Strategic Developments - The initiative is supported by the projected growth of the global incretin market, which could reach $200 billion by 2030, with an estimated 25 million Americans potentially receiving GLP-1 treatment by that year [2] - Artelo's strategy focuses on the intersection of biology, clinical need, and commercial opportunity, aiming to establish a prominent role in the GLP-1 treatment landscape [4][6] Group 2: Clinical and Research Insights - Analyses indicate that loss of lean body mass is a significant issue with GLP-1 therapies, highlighting the need for solutions that can help preserve muscle [3][4] - ART27.13 has shown promising results in interim CAReS data, with patients experiencing an average weight gain of approximately 6% compared to a 5% weight loss in placebo-treated patients [5][7] Group 3: Intellectual Property and Research Initiatives - A provisional patent application has been filed covering the use of cannabinoid receptor agonism to prevent muscle loss associated with GLP-1 therapy [6] - A non-clinical study is set to evaluate ART27.13 in models relevant to GLP-1-associated muscle preservation, further supporting its potential utility [6]

Core Viewpoint - Prairie Operating Co. has announced an extension of the anniversary warrant issuance date for its Series F Convertible Preferred Stock from March 26, 2026, to April 7, 2026, to allow for continued discussions between the parties involved [1][2]. Company Overview - Prairie Operating Co. is an independent energy company based in Houston, focused on the development and acquisition of oil and natural gas resources in the United States, particularly in the Denver-Julesburg (DJ) Basin [3]. - The company's operations are concentrated in oil and liquids-rich regions, with a primary focus on the Niobrara and Codell formations [3]. - Prairie is committed to responsible resource development, aiming to maximize returns through consistent growth, capital discipline, and sustainable cash flow generation [3].

Core Viewpoint - Outlook Therapeutics, Inc. has successfully closed a public offering of 20 million shares of common stock and accompanying warrants, raising a total of $5.0 million in gross proceeds, which will be used primarily for working capital and general corporate purposes [1][2]. Group 1: Offering Details - The public offering consisted of 20,000,000 shares of common stock sold at a combined price of $0.25 per share, along with warrants to purchase an additional 20,000,000 shares at the same exercise price [1]. - The total gross proceeds from the offering were $5.0 million, with potential additional proceeds of approximately $5.0 million if the common warrants are fully exercised [2]. - H.C. Wainwright & Co. acted as the exclusive placement agent for this offering [3]. Group 2: Company Overview - Outlook Therapeutics is focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg), aimed at enhancing the standard of care for retinal diseases [6]. - LYTENAVA™ is the first ophthalmic formulation of bevacizumab to receive marketing authorization in Europe for the treatment of wet age-related macular degeneration (AMD) [6]. - In the U.S., ONS-5010/LYTENAVA™ is currently investigational and, if approved, would be the first approved ophthalmic formulation of bevacizumab for retinal indications [7].

Core Viewpoint - Burke & Herbert Financial Services Corp. and LINKBANCORP, Inc. have announced the approval of their merger by shareholders, with Burke & Herbert as the continuing corporation, pending regulatory approvals and customary closing conditions [1] Company Overview - Burke & Herbert Financial Services Corp. is the financial holding company for Burke & Herbert Bank & Trust Company, the oldest continuously operating bank under its original name in the greater Washington, D.C. area, with over 75 branches across five states [2] - LINKBANCORP, Inc. was established in 2018, focusing on community banking, with its subsidiary LINKBANK serving clients in Pennsylvania, Maryland, Delaware, and Virginia through 24 client solutions centers [3]

Core Insights - Firefly Aerospace supported Lockheed Martin in two responsive space exercises for the U.S. Space Force as part of the VICTUS DIEM mission [2][5] Group 1: Exercise Details - The first exercise demonstrated rapid payload processing, completing spacecraft arrival operations, checkouts, mating, and encapsulation in under 12 hours [3] - The second exercise involved a 36-hour rapid launch simulation to practice emergency launch protocols for tactically responsive space missions in real threat scenarios [3] Group 2: Collaboration and Mission Design - Collaboration with Space System Command's System Delta 89 and Space Launch Delta 30 led to the completion of mission design, flight trajectory planning, launch collision avoidance analysis, and range safety protocols within 36 hours of a simulated notice to launch [4] Group 3: VICTUS DIEM Program - VICTUS DIEM aims to enhance rapid launch capabilities through commercial partnerships within the government process, focusing on refining a repeatable process for rapid launch as part of the broader VICTUS program [5] Group 4: Company Overview - Firefly Aerospace is a leading space and defense technology company, enabling government and commercial customers to launch, land, and operate in space [6] - The company is the only commercial entity capable of launching a satellite to orbit with approximately 24-hour notice and has achieved a fully successful landing on the Moon [6] - Established in 2017, Firefly's facilities in central Texas support rapid innovation, with a focus on small- to medium-lift launch vehicles, lunar landers, and orbital vehicles [6]

Core Insights - The company Minerva Neurosciences, Inc. presented clinical data from a safety trial evaluating the co-administration of roluperidone and olanzapine at the 2026 Schizophrenia International Research Society Annual Congress [1][2] - The confirmatory Phase 3 trial is currently enrolling participants, with topline data expected in the second half of 2027 [1] Study Findings - The trial assessed potential interactions between roluperidone and olanzapine, a widely used antipsychotic, and found no clinically significant adverse effects [2] - There were no meaningful pharmacokinetic (PK) or pharmacodynamic (PD) changes observed during the combined administration of the two drugs [2] Presentation Details - The presentation titled "A Study of Roluperidone Coadministered with Olanzapine in Patients with Negative Symptoms of Schizophrenia" was delivered by Michael Davidson, MD, Chief Medical Officer of Minerva Neurosciences [2][6] - The presentation took place on March 26, 2026, during the Pharmaceutical Pipeline session [6]

Core Insights - LogicMark, Inc. reported a 36% increase in fourth-quarter revenue, reaching $3.1 million, and a 15% increase in full-year revenue to $11.4 million, driven by strong sales of its product lineup [10][11][15] - The company's gross margin improved to 69.8% in the fourth quarter, up from 66.3% year-over-year, reflecting a favorable product mix [12][10] - LogicMark is focusing on expanding distribution channels and enhancing its product offerings, including a new wearable watch and a connected-home hub [5][6] Financial Highlights - Fourth-quarter revenue was $3.1 million, a 36% increase from $2.2 million in the same period last year [11] - Full-year revenue increased to $11.4 million from $9.9 million, marking a 15% growth [15] - Gross profit for the fourth quarter rose 43% to $2.1 million, with a full-year gross profit of $7.6 million, up from $6.6 million [12][15] - Operating expenses for the fourth quarter were $3.8 million, a modest increase of 3% compared to the previous year [12] - The net loss for the fourth quarter improved to $1.6 million from $3.7 million in the prior-year period [13] Operational Highlights - The company is enhancing its platform for proactive, data-driven care with new solutions in the pipeline, including a wearable watch and a connected-home hub [6][8] - LogicMark's product portfolio includes the Freedom Alert Max, which features health-tracking capabilities [7] - The company is expanding its presence in healthcare, government, and consumer channels, supported by a renewed GSA contract [5][10] Market Position - LogicMark is positioned to capitalize on the growing personal emergency response and connected-care market, driven by trends in aging in place and at-home care [10] - The company has a healthy balance sheet with $9.5 million in cash and no long-term debt as of December 31, 2025 [14] - LogicMark's strategy includes moving from reactive alerting to proactive, predictive care through advanced technologies [10][8]

Core Viewpoint - Orezone Gold Corporation has successfully acquired Hecla Quebec Inc., gaining full ownership of the Casa Berardi gold mine and a portfolio of exploration properties in Quebec, marking a strategic expansion into a Tier 1 mining jurisdiction [1][2]. Transaction Summary - The total consideration for the acquisition amounts to $352 million, with an additional contingent consideration of up to $241 million [4]. - The company paid $160 million in cash and issued 65,757,265 common shares, representing 9.9% of Orezone's post-closing shares [5]. - Deferred cash payments of $80 million are due at 18 and 30 months post-closing, with contingent payments linked to gold prices and future production from the Casa Berardi mine [5]. Transaction Financing - The acquisition is financed through Orezone's strong balance sheet and free cash flow from its Bomboré mine, with an upfront deposit of $100 million provided by Franco-Nevada Corporation as part of a gold stream agreement [6][8]. Operational Focus - Orezone's immediate focus at Casa Berardi will be to optimize operations and conduct trade-off studies to enhance underground production [3][15]. - A multi-year exploration drill program targeting 80,000 to 100,000 meters annually will commence, focusing on high-grade extensions and near-mine mineralization [3][15]. Asset Overview - The Casa Berardi mine has produced over 3.2 million ounces of gold and has established resources of 1.2 million ounces in both measured and indicated categories, as well as in proven and probable reserves [7]. - The acquisition includes additional exploration projects such as Heva-Hosco and Duverny, which have significant resource potential [7]. Future Plans - The integration of the Casa Berardi operation into Orezone is planned for 2026, with updated guidance to be provided in the second quarter [15]. - The company aims to publish an updated mine plan and economic study by the fourth quarter of 2026 [15].